Non-cardiac infarction
Conditions
Interventions
Precision Antiplatelet Therapy Trial Group:Platelet function testing guides antiplatelet drug selection
Traditional Antiplatelet Therapy Control Group:Aspirin 100mg orally once a day
Sponsors
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, the First Affiliated Hospital of Chengdu Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged from 18 to 80 years; 2. Diagnosed with non-cardiogenic ischemic stroke according to WHO criteria, confirmed by cranial CT or MRI to exclude hemorrhagic stroke.; 3. First stroke onset >= 1 month and <=3 months; 4. mRS Score <= 2 points; 5. Undergoing antiplatelet therapy with 100mg aspirin daily for at least 8 days; 6. Informed consent signed by the patient or their family member.
Exclusion criteria
Exclusion criteria: 1. History of recurrent stroke. 2. History of gastrointestinal bleeding, intracranial hemorrhage, or other bleeding disorders. 3. Contraindications or intolerance to antiplatelet therapy medications. 4. Severe cardiac, pulmonary, hepatic, or renal insufficiency, or presence of severe comorbid conditions (e.g., end-stage malignant tumors, severe single/multiple organ failure). 5. Poor compliance, inability to cooperate with study requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of platelet hyperreactivity (HOPR) in patients enrolled for 30 ± 5 days; | — |
Secondary
| Measure | Time frame |
|---|---|
| Major ischemic events and major bleeding events, including cardiovascular and cerebrovascular death, myocardial infarction, stroke, emergency intervention, stent thrombosis, and academic research alliance standard (BARC) grade 2 or above bleeding.; | — |
Countries
China
Contacts
Public ContactYang Jie, Lin Yapeng
Sichuan Academy of Medical Sciences / Sichuan Provincial People's Hospital, the First Affiliated Hospital of Chengdu Medical College
Outcome results
None listed